Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

NDCN researchers lead a global study based on analysing survey data

Close up of hands of two people working at desk with laptops and papers

Dr Arjune Sen heads up the Oxford Epilepsy Research Group. In partnership with local charity SUDEP Action, he will lead a project to investigate how COVID-19 has impacted on people with epilepsy, their carers and health care workers. In particular, they are interested in assessing escalation and mitigation of risk.

The team will be addressing this question using data from across the globe. They will employ surveys using the online JISC platform - pilot surveys are currently being reviewed and translated into multiple languages. The data will be entered anonymously and analysed in aggregated. It is hoped that as many as 500 participants will be engaged.

The aim is to use the findings to make specific recommendations on how to manage risk in people with epilepsy during the coronavirus pandemic and beyond. The team will highlight challenges and opportunities in a global context which can inform and improve patient care and help save lives.

Initially this work will be funded by the Oxfordshire Biomedical Research Centre and SUDEP Action. Collaborators include University College London and Professor Charles Newton from the Department of Psychiatry at the University of Oxford.

 

 

Similar stories

New spinout company: Human-Centric Drug Discovery

Human-Centric Drug Discovery is a new Oxford University spinout company from Professor Zameel Cader's lab.

Funding received for research into Motor Neuron Disease

A £210,000 donation from the Alan Davidson Foundation has been made to our Department to advance our world-leading research into Motor Neuron Disease. The funding will support a project manager to deliver an innovative research project using the genetic causes of MND to develop approaches to early diagnosis.

Research finds drug may benefit some patients hospitalised with COVID-19 pneumonia

A proof-of-concept trial involving Oxford researchers has identified a drug that may benefit some patients hospitalised with COVID-19 pneumonia.

Protein test could lead to earlier and better diagnosis of Parkinson’s

Scientists have observed the clumping of alpha-synuclein in the cerebrospinal fluid taken from people with Parkinson's. The findings offer hope that a pioneering new clinical test could be developed to diagnose Parkinson's correctly in its early stages.

Nine new Professors

Many congratulations to the following members of our Department who have been awarded the title of Professor in the recent Recognition of Distinction round.

Evaluating risk to people with epilepsy during the COVID-19 pandemic - study wins international prize

In May 2020 our researchers initiated a global project to investigate how COVID-19 has affected people with epilepsy, their carers and health care workers.